

# Bartolome R Celli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5873063/bartolome-r-celli-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

359  
papers

30,466  
citations

79  
h-index

172  
g-index

398  
ext. papers

36,549  
ext. citations

8  
avg, IF

6.94  
L-index

#	Paper	IF	Citations
359	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASC Trial.. <i>International Journal of COPD</i> , <b>2022</b> , 17, 273-282	3	
358	The 7 Cardinal Sins of COPD in Spain.. <i>Archivos De Bronconeumologia</i> , <b>2022</b> ,	0.7	
357	Comorbidities in Patients With Chronic Obstructive Pulmonary Disease <b>2022</b> , 663-674		
356	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	6
355	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	7
354	Improving lung health in low-income and middle-income countries: from challenges to solutions. <i>Lancet, The</i> , <b>2021</b> , 397, 928-940	40	57
353	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. <i>Respirology</i> , <b>2021</b> , 26, 532-551	3.6	11
352	Reply to Thomson, to Neder ., and to Wouters. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 112	10.2	
351	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	2
350	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. <i>Lancet Respiratory Medicine,the</i> , <b>2021</b> , 9, 1288-1298	35.1	15
349	Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. <i>Chest</i> , <b>2021</b> , 160, e389-e397	5.3	0
348	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 89, 3-9	3.9	3
347	Executive Summary: Optimal NIV Medicare Access Promotion: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. <i>Chest</i> , <b>2021</b> , 160, 1808-1821	5.3	0
346	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 689-698	10.2	10
345	From GOLD 0 to Pre-COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 414-423	10.2	26
344	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASC randomised controlled trial. <i>European Respiratory Journal</i> , <b>2021</b> , 57,	13.6	7
343	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 36-41	0.7	3

342	Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. <i>Respiration</i> , <b>2021</b> , 100, 93-95	3.7	1
341	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex. <i>Chest</i> , <b>2021</b> , 160, 481-490	5.3	3
340	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 533-533	0.7	
339	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 533-539	0.7	1
338	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. <i>Annals of the American Thoracic Society</i> , <b>2021</b> ,	4.7	1
337	Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 651-666	10.2	12
336	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 1251-1258	10.2	10
335	Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. <i>Chest</i> , <b>2021</b> , 160, 872-878	5.3	4
334	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. <i>Archivos De Bronconeumologia</i> , <b>2021</b> , 57, 36-41	0.7	0
333	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
332	Machine Learning and Prediction of All-Cause Mortality in COPD. <i>Chest</i> , <b>2020</b> , 158, 952-964	5.3	15
331	Smoking Pattern in Men and Women: A Possible Contributor to Sex Differences in Smoke-related Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 1048-1051	10.2	5
330	FEV is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1135-1142	3	11
329	Inhaler device feature preferences among patients with obstructive lung diseases: A systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2020</b> , 99, e20718	1.8	3
328	Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. <i>Respiratory Research</i> , <b>2020</b> , 21, 26	7.3	1
327	Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis. <i>Chronic Respiratory Disease</i> , <b>2020</b> , 17, 1479973119901234	3	14
326	Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, 405-419	5.3	11
325	ADAM15 expression is increased in lung CD8 T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. <i>Respiratory Research</i> , <b>2020</b> , 21, 188	7.3	3

324	Methods for a Seamless Transition From Tracheostomy to Spontaneous Breathing in Patients With COVID-19. <i>Respiratory Care</i> , <b>2020</b> , 65, 1773-1783	2.1	3
323	Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, e74-e87	10.2	31
322	Sex differences between women and men with COPD: A new analysis of the 3CIA study. <i>Respiratory Medicine</i> , <b>2020</b> , 171, 106105	4.6	17
321	Somatotypes trajectories during adulthood and their association with COPD phenotypes. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
320	A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients. <i>International Journal of COPD</i> , <b>2020</b> , 15, 1801-1811	3	0
319	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 158-170	35.1	35
318	Urgent need of a management plan for survivors of COVID-19. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	4
317	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <i>Archivos De Bronconeumologia</i> , <b>2019</b> , 55, 409-413	0.7	
316	Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1257-1266	59.2	136
315	Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. <i>International Journal of COPD</i> , <b>2019</b> , 14, 1019-1031	3	4
314	It's more than low BMI: prevalence of cachexia and associated mortality in COPD. <i>Respiratory Research</i> , <b>2019</b> , 20, 100	7.3	34
313	Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2019</b> , 16, 140-151	2	1
312	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1023-1034	59.2	94
311	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. <i>BMJ Open Respiratory Research</i> , <b>2019</b> , 6, e000431	5.6	18
310	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. <i>ERJ Open Research</i> , <b>2019</b> , 5,	3.5	3
309	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	722
308	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2019</b> , 16, 8-17	2	4
307	Regional differences in rate of FEV decline in COPD: lessons from SUMMIT. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	1

306	Prognostic Validation Using GesEPOC 2017 Severity Criteria. <i>Archivos De Bronconeumologia</i> , <b>2019</b> , 55, 409-413	0.7	10
305	The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 641-644	4.7	3
304	The most beautiful COPD chart in the world: all together to end COPD!. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	8
303	Plasma metabolomics and clinical predictors of survival differences in COPD patients. <i>Respiratory Research</i> , <b>2019</b> , 20, 219	7.3	13
302	Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , <b>2019</b> , 6, 267-280	2.7	18
301	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1195-1204	10.2	49
300	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 29-39	4.7	8
299	Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 301-303	4.7	3
298	βBlocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 608-614	4.7	14
297	COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018758528	2.7	61
296	COPD: time to improve its taxonomy?. <i>ERJ Open Research</i> , <b>2018</b> , 4,	3.5	43
295	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 51-57	10.2	97
294	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1540-1551	10.2	94
293	Long-Acting βAgonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 1641-1644	10.2	3
292	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	38
291	Cigarette smoking and response to inhaled corticosteroids in COPD. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	17
290	A Historical Perspective of Pulmonary Rehabilitation <b>2018</b> , 3-18		1
289	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. <i>BMC Medicine</i> , <b>2018</b> , 16, 33	11.4	14

288	Shorter telomeres in non-smoking patients with airflow limitation. <i>Respiratory Medicine</i> , <b>2018</b> , 138, 123-128	10.2	4
287	Reply to Voelkel: Cigarette Smoke Is an Endothelial Cell Toxin. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 274-275	10.2	1
286	Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 433-449	10.2	35
285	The effect of emphysema on readmission and survival among smokers with heart failure. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201376	3.7	3
284	Precision medicine in COPD exacerbations. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 657-659	35.1	14
283	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1000-1011	10.2	56
282	The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1449-1451	10.2	12
281	Pharmacological Therapy of COPD: Reasons for Optimism. <i>Chest</i> , <b>2018</b> , 154, 1404-1415	5.3	15
280	Supplementation with Qter and Creatine improves functional performance in COPD patients on long term oxygen therapy. <i>Respiratory Medicine</i> , <b>2018</b> , 142, 86-93	4.6	16
279	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 1126-1137	15.1	31
278	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 3128-3134	9.5	17
277	Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193143	3.7	35
276	Pulmonary arterial enlargement predicts long-term survival in COPD patients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195640	3.7	9
275	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 47-55	10.2	34
274	Chronic Obstructive Pulmonary Disease in Hispanics. A 9-Year Update. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 15-21	10.2	12
273	Network Analysis of Autopsy Diagnoses: Insights into the "Cause of Death" from Unbiased Disease Clustering. <i>Journal of Pathology Informatics</i> , <b>2018</b> , 9, 35	4.4	
272	Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 463-469	10.2	53
271	Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. <i>International Journal of COPD</i> , <b>2018</b> , 13, 3971-3981	3	38

270	Functional Studies of Single-Nucleotide Polymorphisms Suggest Heterogeneity in Chronic Obstructive Pulmonary Disease due to Susceptibility of Different Cell Types. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, S285-S285	4.7	78
269	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT trial. <i>Respiratory Research</i> , <b>2018</b> , 19, 196	7.3	12
268	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	102
267	The Challenge of Controlling the COPD Epidemic: Unmet Needs. <i>American Journal of Medicine</i> , <b>2018</b> , 131, 1-6	2.4	16
266	Prevalence of paradoxical bronchoconstriction after inhaled albuterol. <i>Respiratory Medicine</i> , <b>2018</b> , 141, 100-102	4.6	4
265	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , <b>2017</b> , 22, 575-601	3.6	228
264	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	398
263	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 557-582	10.2	1682
262	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	27
261	Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. <i>Thorax</i> , <b>2017</b> , 72, 117-121	7.3	35
260	Reply: Controlled Clinical Trials and Real-Life Experience with Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 797	10.2	
259	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. <i>Heart</i> , <b>2017</b> , 103, 1536-1542	5.1	34
258	Effect of a single exacerbation on decline in lung function in COPD. <i>Respiratory Medicine</i> , <b>2017</b> , 128, 85-91	4.6	30
257	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	247
256	Telomere length, COPD and emphysema as risk factors for lung cancer. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	11
255	A simple algorithm for the identification of clinical COPD phenotypes. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	35
254	The EASI model: A first integrative computational approximation to the natural history of COPD. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185502	3.7	3
253	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. <i>Lancet, The</i> , <b>2017</b> , 390, 980-987	4.0	52

252	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 574-582 <sup>9.7</sup>		
251	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 415-416	0.7	
250	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 574-582 <sup>9.7</sup>		1
249	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. <i>Respiratory Medicine</i> , <b>2017</b> , 131, 27-34	4.6	21
248	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	84
247	Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. <i>Respiratory Research</i> , <b>2017</b> , 18, 59	7.3	30
246	Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. <i>Chest</i> , <b>2017</b> , 151, 358-365	5.3	21
245	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 881-888	10.2	38
244	Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 622-629	10.2	64
243	Natural history of COPD: gaps and opportunities. <i>ERJ Open Research</i> , <b>2017</b> , 3,	3.5	23
242	Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. <i>Respiratory Research</i> , <b>2017</b> , 18, 175	7.3	9
241	Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life. <i>BMJ Open Respiratory Research</i> , <b>2017</b> , 4, e000194	5.6	0
240	Perception of symptoms and quality of life - comparison of patients and physicians' views in the COPD MIRROR study. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2189-2196	3	31
239	Impact and prevention of severe exacerbations of COPD: a review of the evidence. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2891-2908	3	102
238	Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting $\beta$ -agonists. <i>Journal of Medical Economics</i> , <b>2016</b> , 19, 11-20	2.4	5
237	DNA methylation profiling in human lung tissue identifies genes associated with COPD. <i>Epigenetics</i> , <b>2016</b> , 11, 730-739	5.7	48
236	Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. <i>Respiratory Research</i> , <b>2016</b> , 17, 147	7.3	25
235	What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 664-73	13.6	229



234	The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life. <i>Multidisciplinary Respiratory Medicine</i> , <b>2016</b> , 11, 10	3	2
233	Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT <sup>®</sup> trial. <i>Respiratory Research</i> , <b>2016</b> , 17, 48	7.3	6
232	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 1483-1493	10.2	57
231	Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 869-83	6.4	42
230	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 672-81	27.4	209
229	Handgrip weakness and mortality risk in COPD: a multicentre analysis. <i>Thorax</i> , <b>2016</b> , 71, 86-7	7.3	41
228	Identification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance System. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla.)</i> , <b>2016</b> , 3, 620-627	2.7	11
227	Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. <i>International Journal of COPD</i> , <b>2016</b> , 11, 1217-22	3	10
226	Is COPD a Progressive Disease? A Long Term Bode Cohort Observation. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151856	3.7	7
225	Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. <i>Chest</i> , <b>2016</b> , 149, 936-42	5.3	43
224	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1635-44	13.6	29
223	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1817-26	40	263
222	Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. <i>Chest</i> , <b>2016</b> , 150, 869-876	5.3	8
221	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , <b>2016</b> , 119, 87-95	4.6	21
220	Protective role for club cell secretory protein-16 (CC16) in the development of COPD. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 1544-56	13.6	79
219	Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. <i>Annals of the American Thoracic Society</i> , <b>2015</b> , 12, 303-12	4.7	93
218	A novel nonhuman primate model of cigarette smoke-induced airway disease. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 741-55	5.8	23
217	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. <i>Lancet Respiratory Medicine</i> , <b>2015</b> , 3, 443-50	35.1	98

216	Clinical and prognostic heterogeneity of C and D GOLD groups. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 250-4	13.6	11
215	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 111-22	59.2	595
214	COPD comorbidities network. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 640-50	13.6	94
213	Recommendations for the early diagnosis of COPD: the AIMAR view. <i>Multidisciplinary Respiratory Medicine</i> , <b>2015</b> , 10, 6	3	4
212	Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , <b>2015</b> , 147, 883-893	5.3	44
211	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 191, e4-e27	10.2	137
210	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 879-905	13.6	107
209	Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1501-3	13.6	11
208	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1138-46	4.6	56
207	Continuous fat-free mass decline in COPD: fact or fiction?. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1496-83.6	13.6	10
206	Maximal Oxygen Uptake--Risk Predictor of NSCLC Resection in Patients With Comorbid Emphysema: Lessons From NETT. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2015</b> , 27, 225-31	1.7	5
205	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. <i>BMC Pulmonary Medicine</i> , <b>2015</b> , 15, 145	3.5	9
204	Chronic obstructive pulmonary disease. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15076	51.1	270
203	COPD (confusion over proper diagnosis) in the zone of maximum uncertainty. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1525-6	13.6	4
202	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2015</b> , 10, 549-64	3	24
201	B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 695-705	10.2	61
200	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , <b>2015</b> , 24, 159-72	9.8	50
199	Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , <b>2015</b> , 147, 894-942	5.3	169

198	We must join forces in the battle against COPD. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 1528	13.6	
197	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT <sup>®</sup> Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2015</b> , 2, 122-130	2.7	5
196	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT <sup>®</sup> Randomized Controlled Trial. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2015</b> , 2, 236-251	2.7	3
195	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. <i>Thorax</i> , <b>2014</b> , 69, 718-23	7.3	118
194	Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. <i>Thorax</i> , <b>2014</b> , 69, 799-804	7.3	63
193	Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 1180-8	4.6	12
192	Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 1022-30	10.2	117
191	Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study. <i>Npj Primary Care Respiratory Medicine</i> , <b>2014</b> , 24, 14075	3.2	9
190	Native American ancestry, lung function, and COPD in Costa Ricans. <i>Chest</i> , <b>2014</b> , 145, 704-710	5.3	22
189	Rebuttal from Dr. Celli. <i>Chest</i> , <b>2014</b> , 145, 1195-1196	5.3	
188	Counterpoint: Should storefront clinics provide case finding and chronic care for COPD? No. <i>Chest</i> , <b>2014</b> , 145, 1193-1194	5.3	2
187	Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. <i>Chest</i> , <b>2014</b> , 145, 695-703	5.3	46
186	Obstructive lung disease in Mexican Americans and non-Hispanic whites: an analysis of diagnosis and survival in the National Health and Nutritional Examination Survey III Follow-up Study. <i>Chest</i> , <b>2014</b> , 145, 282-289	5.3	14
185	Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. <i>Chest</i> , <b>2014</b> , 145, 981-991	5.3	129
184	Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 324-31	13.6	35
183	Sexually-dimorphic targeting of functionally-related genes in COPD. <i>BMC Systems Biology</i> , <b>2014</b> , 8, 118	3.5	38
182	Longitudinal assessment in COPD patients: multidimensional variability and outcomes. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 745-53	13.6	26
181	Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. <i>PLoS ONE</i> , <b>2014</b> , 9, e89866	3.7	35

180	Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , <b>2014</b> , 1, 229-238	2.7	30
179	The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2013</b> , 7, 57-64	3.8	23
178	The club cell and its protein, CC16: time to shine. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 757-9	35.1	7
177	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1376-84	4.6	243
176	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 1017-22	13.6	65
175	The COPD Biomarker Qualification Consortium (CBQC). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2013</b> , 10, 367-77	2	57
174	Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 702-7	4.6	46
173	Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 1904-11	4.6	15
172	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 129-36	35.1	183
171	Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 382-6	10.2	206
170	Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. <i>Chest</i> , <b>2013</b> , 143, 694-702	5.3	101
169	Multicomponent indices to predict survival in COPD: the COCOMICS study. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 323-32	13.6	70
168	Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes?. <i>Annals of Nutrition and Metabolism</i> , <b>2013</b> , 63, 239-47	4.5	34
167	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 636-46	13.6	139
166	Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. <i>Chest</i> , <b>2013</b> , 144, 490-497	5.3	41
165	Characterizing functional lung heterogeneity in COPD using reference equations for CT scan-measured lobar volumes. <i>Chest</i> , <b>2013</b> , 143, 1607-1617	5.3	9
164	Epicardial adipose tissue in patients with chronic obstructive pulmonary disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e65593	5.3	13
163	Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. <i>F1000Research</i> , <b>2013</b> , 2, 114	3.6	4

162	Systemic biomarkers in the evaluation and management of COPD patients: are we getting closer to clinical application?. <i>Current Drug Targets</i> , <b>2013</b> , 14, 177-91	3	22
161	Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 1238-47	10.2	88
160	Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. <i>Journal of the American Medical Directors Association</i> , <b>2012</b> , 13, 291-7	5.9	167
159	Treatment of the Stable Patient with Chronic Obstructive Pulmonary Disease <b>2012</b> , 553-561		
158	Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 185, 1065-72	10.2	288
157	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2012</b> , 13, 66	7.3	14
156	Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 155-61	10.2	716
155	Health effects of the Federal Bureau of Prisons tobacco ban. <i>BMC Pulmonary Medicine</i> , <b>2012</b> , 12, 64	3.5	3
154	Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. <i>Proceedings of the American Thoracic Society</i> , <b>2012</b> , 9, 74-9		22
153	The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. <i>Chest</i> , <b>2012</b> , 142, 1027-1034	5.3	29
152	Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. <i>PLoS ONE</i> , <b>2012</b> , 7, e37483	3.7	521
151	Six-minute walking distance in women with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 300-5	2	8
150	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 580-7	4.6	87
149	Prognostic assessment in COPD: health related quality of life and the BODE index. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 916-21	4.6	43
148	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 1176-88	4.6	23
147	Premature discontinuation during the UPLIFT study. <i>Respiratory Medicine</i> , <b>2011</b> , 105, 1523-30	4.6	17
146	Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. <i>PLoS ONE</i> , <b>2011</b> , 6, e16021	3.7	38
145	Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. <i>Respirology</i> , <b>2011</b> , 16, 825-35	3.6	39

144	Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. <i>Clinical Respiratory Journal</i> , <b>2011</b> , 5, 44-9	1.7	55
143	Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. <i>Respiratory Research</i> , <b>2011</b> , 12, 129	7.3	18
142	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. <i>Respiratory Research</i> , <b>2011</b> , 12, 71	7.3	54
141	Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 317-22	10.2	122
140	The EXACT-Pro: measuring exacerbations of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 287-8	10.2	11
139	Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2011</b> , 45, 304-10	5.7	43
138	The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 1015-21	10.2	155
137	Bronchodilator reversibility in COPD. <i>Chest</i> , <b>2011</b> , 140, 1055-1063	5.3	60
136	Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 1129-37	10.2	135
135	Changes in forced expiratory volume in 1 second over time in COPD. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1184-92	59.2	654
134	Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 913-9	10.2	205
133	Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2011</b> , 8, 121-35	2	38
132	Management Guidelines for Chronic Obstructive Pulmonary Disease <b>2011</b> , 81-98		
131	Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 325-31	10.2	433
130	Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 1004-10	10.2	59
129	Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 849-57	4.6	148
128	Predictors of mortality in COPD. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 773-9	4.6	117
127	Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 1495-504	4.6	58

126	Chronic obstructive pulmonary disease phenotypes: the future of COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 182, 598-604	10.2	678
125	Cardiovascular events in patients with COPD: TORCH study results. <i>Thorax</i> , <b>2010</b> , 65, 719-25	7.3	142
124	Lung volume reduction therapies for advanced emphysema: an update. <i>Chest</i> , <b>2010</b> , 138, 407-17	5.3	41
123	Characterisation of COPD heterogeneity in the ECLIPSE cohort. <i>Respiratory Research</i> , <b>2010</b> , 11, 122	7.3	752
122	Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. <i>Chest</i> , <b>2009</b> , 136, 1456-1465	5.3	202
121	Effect of Pharmacotherapy on Rate of Decline of FEV1 in the TORCH Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 426-427	10.2	
120	Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 948-55	10.2	209
119	Prediction of risk of COPD exacerbations by the BODE index. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 373-8	4.6	97
118	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , <b>2009</b> , 10, 59	7.3	234
117	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 1171-8	4.0	365
116	Prognostic assessment of patients with COPD. <i>Lancet, The</i> , <b>2009</b> , 374, 1885; author reply 1886-7	4.0	9
115	Does pharmacotherapy reduce the rate of decline of lung function in COPD?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 171; author reply 171-2	10.2	1
114	Women with chronic obstructive pulmonary disease: an emerging phenotype of the disease. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2009</b> , 6, 821-830		2
113	Novel concepts in the pharmacotherapy of chronic obstructive pulmonary disease. <i>Pneumonologia i Alergologia Polska</i> , <b>2009</b> , 77, 82-90		1
112	A 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1543-54	59.2	1658
111	Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO <sub>2</sub> between 60 and 70mmHg. <i>Respiratory Medicine</i> , <b>2008</b> , 102, 1026-32	4.6	26
110	Predictors of Survival in COPD: more than just the FEV1. <i>Respiratory Medicine</i> , <b>2008</b> , 102 Suppl 1, S27-35	4.6	92
109	Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. <i>Chest</i> , <b>2008</b> , 134, 746-752	5.3	199

108	Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 332-8	10.2	566
107	Longitudinal change in the BODE index predicts mortality in severe emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 491-9	10.2	97
106	Update on the management of COPD. <i>Chest</i> , <b>2008</b> , 133, 1451-1462	5.3	87
105	C-reactive protein levels and survival in patients with moderate to very severe COPD. <i>Chest</i> , <b>2008</b> , 133, 1336-1343	5.3	109
104	Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. <i>Current Respiratory Medicine Reviews</i> , <b>2008</b> , 4, 312-320	0.3	
103	Profiling serum biomarkers in patients with COPD: associations with clinical parameters. <i>Thorax</i> , <b>2007</b> , 62, 595-601	7.3	140
102	Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2007</b> , 8, 18	7.3	42
101	Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. <i>Chest</i> , <b>2007</b> , 131, 1108-13	5.3	104
100	Differences in cardiopulmonary exercise test results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease stage categories and gender. <i>Chest</i> , <b>2007</b> , 132, 1204-11	5.3	41
99	Impact of COPD exacerbations on patient-centered outcomes. <i>Chest</i> , <b>2007</b> , 131, 696-704	5.3	172
98	Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. <i>Chest</i> , <b>2007</b> , 131, 37-43	5.3	89
97	The 6-min walk distance, peak oxygen uptake, and mortality in COPD. <i>Chest</i> , <b>2007</b> , 132, 1778-85	5.3	180
96	Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 775-89	59.2	2457
95	Predictors of mortality in chronic obstructive pulmonary disease. <i>Clinics in Chest Medicine</i> , <b>2007</b> , 28, 515-24, v	5.3	20
94	COPD heterogeneity: gender differences in the multidimensional BODE index. <i>International Journal of COPD</i> , <b>2007</b> , 2, 151-5	3	4
93	Predicting mortality in chronic obstructive pulmonary disease: chasing the "Holy Grail". <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1298-9	10.2	3
92	Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 461-5		41
91	Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 465-6		25



90	Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 58-65		39
89	Gender associated differences in determinants of quality of life in patients with COPD: a case series study. <i>Health and Quality of Life Outcomes</i> , <b>2006</b> , 4, 72	3	70
88	American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1390-413	10.2	1361
87	Markers of disease severity in chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2006</b> , 19, 189-99	3.5	112
86	Change in the BODE index reflects disease modification in COPD: lessons from lung volume reduction surgery. <i>Chest</i> , <b>2006</b> , 129, 835-6	5.3	20
85	Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. <i>Chest</i> , <b>2006</b> , 130, 647-56	5.3	171
84	Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. <i>Respiratory Care</i> , <b>2006</b> , 51, 1120-4	2.1	61
83	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , <b>2005</b> , 99, 1546-54	4.6	49
82	Future perspectives in COPD. <i>Respiratory Medicine</i> , <b>2005</b> , 99 Suppl B, S41-8	4.6	13
81	Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. <i>American Journal of Medicine</i> , <b>2005</b> , 118, 1364-72	2.4	125
80	Gender and COPD in patients attending a pulmonary clinic. <i>Chest</i> , <b>2005</b> , 128, 2012-6	5.3	182
79	New treatment strategies for COPD. Pairing the new with the tried and true. <i>Postgraduate Medicine</i> , <b>2005</b> , 117, 27-34	3.7	3
78	Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 171, 591-7	10.2	394
77	Gene expression profiling of human lung tissue from smokers with severe emphysema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2004</b> , 31, 601-10	5.7	136
76	Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2004</b> , 1, 303-12	2	133
75	The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1005-12	59.2	2702
74	Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. <i>Chest</i> , <b>2003</b> , 124, 1743-8	5.3	226
73	A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 542-57	3.5	22

72	A 62-year-old woman with chronic obstructive pulmonary disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 290, 2721-9	27.4	
71	Pulmonary rehabilitation. <i>Israel Medical Association Journal</i> , <b>2003</b> , 5, 443-8	0.9	1
70	Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. <i>Chest</i> , <b>2002</b> , 121, 1092-8	5.3	171
69	Cough and phlegm are important predictors of health status in smokers without COPD. <i>Chest</i> , <b>2002</b> , 121, 1427-33	5.3	25
68	Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. <i>Chest</i> , <b>2000</b> , 118, 1582-90	5.3	232
67	Ventilatory drive at rest and perception of exertional dyspnea in severe COPD. <i>Chest</i> , <b>1999</b> , 115, 1293-300	5.3	49
66	Pulmonary rehabilitation for COPD. A practical approach for improving ventilatory conditioning. <i>Postgraduate Medicine</i> , <b>1998</b> , 103, 159-60, 167-8, 173-6	3.7	8
65	Lung reduction surgery in severe COPD decreases central drive and ventilatory response to CO <sub>2</sub> . <i>Chest</i> , <b>1997</b> , 112, 902-6	5.3	21
64	Colour Plate Section 893-900		
63	Aerosols and Delivery Systems 481-498		
62	Bronchiectasis and COPD 139-147		1
61	Anticholinergics in COPD 657-668		
60	The Physiology of Breathlessness 20-25		
59	The Physiology of Muscle 26-39		
58	Exercise Limitations and Cardiopulmonary Exercise Testing in COPD 40-62		1
57	The Natural History of COPD 115-123		1
56	Obliterative Bronchiolitis 148-153		
55	Monitoring and Outcomes 181-188		

54	Mucosal Immunity201-211	
53	COPD and Pulmonary Surfactant212-218	
52	The Macrophage and its Role in the Pathogenesis of COPD219-232	
51	Eosinophils and COPD233-244	
50	Airway Epithelial Defence, Repair and Regeneration245-254	
49	The Role of the Neutrophil in the Pathogenesis of COPD255-268	
48	Lymphocytes269-274	1
47	Leukotrienes in COPD: The Unexploited Potential285-299	
46	Cigarette Smoking, Emphysema and Lung Endothelium300-307	
45	Mesenchymal Cells of the Lung308-316	
44	Lung Development317-340	
43	Animal Models341-348	
42	Proteinases and COPD349-366	3
41	Oxidants367-384	1
40	Cigarette Smoke-Induced Disease385-396	1
39	COPD and Air Pollution397-407	1
38	Viruses in COPD408-418	
37	Genetic Factors436-446	

- 36  $\alpha$ -Antitrypsin Deficiency 447-459 1
- 35 Body Weight and Systemic Effects 460-466
- 34 Lung Connective Tissue 467-480
- 33 Gastro-Oesophageal Reflux 499-512
- 32 Upper Airway Diseases 513-527
- 31 Acute Pulmonary Embolism 528-537
- 30 Infection Management and Airflow Obstruction 546-558
- 29 Mechanical Ventilation for Exacerbation of COPD 559-568
- 28 Comorbidity 569-576 1
- 27 Clinical Assessment of Control of Breathing 63-74
- 26 Pulmonary Rehabilitation 585-594
- 25 Social Support 595-600
- 24 Long-Term Invasive Mechanical Ventilation 601-607
- 23 Oxygen Therapy in COPD 622-635
- 22 Surgical Therapy for COPD 636-656
- 21  $\beta$ -Agonists 669-684
- 20 Phosphodiesterase 4 Inhibitors in the Treatment of COPD 708-727
- 19 Physiology and Pathobiology of the Lung Circulation 75-79 1

- 18 Antibiotic Therapy in Patients with COPD728-746
- 17 Antioxidants747-755
- 16 Mucolytics for COPD756-768
- 15 End-Of-Life and Palliative Care for Patients with COPD769-778
- 14 Economic Burden of COPD779-791 2
- 13 Pharmacoepidemiology of COPD792-804
- 12 Social and Behavioural Impact of COPD - Research Opportunities805-810
- 11 Guidelines811-820
- 10 Protease Inhibitors821-844
- 9 Retinoids845-858
- 8 Sleep in Patients with COPD80-89
- 7 Chemokines in COPD859-866 1
- 6 The Physiology of Gas Exchange102-114
- 5 The Physiology of Cough90-101
- 4 COPD and Lung Cancer538-545
- 3 Mucociliary Clearance189-200
- 2 Structure-function Relationships: The Pathophysiology of Airflow Obstruction1-19
- 1 The use of multidimensional indices143-160 1

